FY2026 EPS Estimates for MDGL Cut by Leerink Partnrs
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) – Equities researchers at Leerink Partnrs cut their FY2026 EPS estimates for shares of Madrigal Pharmaceuticals in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical company will earn $1.63 per share for the year, down from […]
More Stories
White House to Hold Meeting on Security Protocols After Shooting, Official Says
By Jack Phillips White House chief of staff Susie Wiles will hold a meeting with the Secret Service and the...
Trump Says First Lady Unharmed, ‘Doing Great’ After White House Correspondents’ Dinner Shooting
By Jack Phillips President Donald Trump on Sunday morning said that First Lady Melania Trump is doing “doing great” and...
People Are Losing Billions Through Social Media Scams, FTC Says
By Jackson Richman Americans are losing billions of dollars to scams that begin on social media, according to new data...
US Accuses China of ‘Industrial-Scale’ AI Theft Ahead of Trump’s Visit
By Michael Zhuang The White House has issued a sharply worded memo accusing China-linked entities of systematically stealing U.S. artificial...
CDC Investigating Multi-State Salmonella Outbreak Linked to Backyard Poultry
By Jack Phillips The Centers for Disease Control and Prevention has said it is investigating an outbreak of salmonella bacterial...
US Allows Venezuela to Fund Maduro’s Defense After Court Challenge
By Tom Gantert The United States will ease sanctions on Venezuela to allow its regime to pay legal fees for...